Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
about
Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIICurrent situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant IIIEfficacy of systemic therapy in advanced pancreatic carcinoma.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.New target agents in the treatment of colorectal cancer patients.Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer.Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.The burden of scientific progress: growing inequalities in the delivery of cancer care.Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.
P2860
Q34568677-C49030EB-1166-4D1E-8C0C-CEC4D1DA3CD1Q34586272-C535F754-60D4-4D63-AC4E-7ACAE8ED10CFQ36088178-EDE90687-F800-418B-8343-B5D588F7A16CQ36425154-82F6F92C-2D39-4322-9780-DF752F34ACD3Q36504349-383873E8-801A-401C-8C8A-A271B7A19D2DQ37392688-2C518B10-0719-454A-A3A6-1846AC8A4007Q37771244-1EADF77D-8F02-4759-BF2A-AA3663F2A4C2Q38089157-4B32180E-8BB3-4C96-9609-F049138DF337Q41129659-777C88DD-95FD-4A29-9183-4A39A78E01A9Q46965188-DA1DDD18-FFD9-4886-AE8F-06DAD42CDD48Q53258385-F4F6C803-59A2-4BE9-B605-FE507C19F665Q54416267-1E1860B9-D224-4C5A-9DC2-FBE9F06A822A
P2860
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@ast
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@en
type
label
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@ast
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@en
prefLabel
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@ast
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@en
P2093
P2860
P921
P1433
P1476
Targeted drugs in metastatic c ...... Acta Oncologica expert report.
@en
P2093
Halfdan Sørbye
Per Pfeiffer
Peter Nygren
Pia Osterlund
P2860
P304
P356
10.1080/02841860510029798
P577
2005-01-01T00:00:00Z